Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa

Rambam Health Care Campus

Status and phase: Withdrawn; Phase 4

Conditions: Epidermolysis Bullosa

Treatments: Drug: tetracyclin

Study type: Interventional

Funder types: Other

Identifiers

NCT00336154

2140CTIL

Details and patient eligibility

About

Epidermolysis Bullosa(EB) is an inherited bullous disease. Tetracycline is believed to have anti inflammatory properties. 20 patients with EB older than 13 years will be treated for 4 months with tetracycline or placebo. After one month of wash out they will be treated for additional 4 m with placebo or tetracycline. The patients will be examined each month to estimate bulla formation,rate of healing .

Full description

Epidermolysis Bullosa(EB) is an inherited bullous disease. Tetracycline is believed to have anti inflammatory properties. 20 patients with EB older than 13 years will be treated for 4 months with tetracycline or placebo. After one month of wash out they will be treated for additional 4 m with placebo or tetracycline. The patients will be examined each month to estimate bulla formation,rate of healing .

Sex: All

Ages: 13 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosed as epidermolysis bullosa
• not pregnant
• active disease
• more than 5 bulla-

Exclusion criteria

• age less than 13
• known sensitivity to tetracyclin
• abnormal liver and kidney tests.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind